ArticleJACC. Case reports2025
A Case of Postural Orthostatic Tachycardia Syndrome in a 20-Year-Old Female Athlete: Review of Ivabradine Guidelines.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostural orthostatic tachycardia syndrome (POTS) is a disorder characterized by orthostatic intolerance, tachycardia, and syncope. Ivabradine, though not Food and Drug Administration approved for POTS, has shown promise in its management. CASE SUMMARY: A 20-year-old woman with POTS, complicated by multiple comorbidities, experienced a severe functional decline. Standard therapies were ineffective. Given the presence of apical trabeculations and severe tachycardia, ivabradine was initiated, leading to rapid and sustained improvements in her symptoms. DISCUSSION: This case highlights the effectiveness of ivabradine in patients with complex POTS who have failed conventional treatments. The patient's dramatic recovery underscores its potential to enhance quality of life. While previous studies support the efficacy of ivabradine in treating POTS, this case reinforces it as a viable treatment option and adds real-world evidence for its inclusion in treatment guidelines. TAKE-HOME MESSAGE: As the understanding of POTS evolves, incorporating ivabradine into treatment guidelines could expand therapeutic options and improve patient outcomes, particularly in refractory cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.